Current research

At ANSTO, radiopharmaceutical development facilities are available to researchers and industry through peer-reviewed, collaborative and commercial arrangements.

ANSTO's radiopharmaceutical development facilities include: Radiopharmaceuticals chemistry, pharmacology, PET/CT and SPECT/CT

Clinical and research communities interested in gaining access to specific radionuclides are welcome to discuss their needs with ANSTO. For example, the organisation has developed a technique for producing of high purity copper-64 and carrier free lutetium-177.

brain
Investigate the effects of long term substance abuse in adolescent and adult rats. More...
sun
Melanoma has a high incidence in Australia compared to other societies. More...
image of brain graphic
Providing for early diagnosis or enhanced patient management. More...

Ionising radiation physics

radiotracer
ANSTO LifeSciences is involved in measuring radiopharmaceutical doses for patients. More...
microscope
Fostering growth of Australian expertise in biomedical imaging.. More...
ray thumbnail
Imaging in vivo is the essential goal of radiopharmaceutical development. More...
neutron
Copper-64 is a radionuclide used by the Australian research community. More...